In anticancer immunity, the immune system recognizes the tumor‐specific antigens expressed through gene mutations, and specific CD8+ cytotoxic T lymphocytes (CTLs) are recruited to the sites of tumor targeting the corresponding antigens.83 Here, CD8A is linked to neoplasm.